

In the claims:

Cancel claims 51-55 as being drawn to a nonelected invention. Also cancel claims 2-4.
Amend claims 1, 36, and 39, and add new claims 56 and 57 as follows:

1. (Currently Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) ~~a mature form of an amino acid sequence of SEQ ID NO:4;~~
 - (b) ~~a variant of a mature form of an amino acid sequence of SEQ ID NO:4, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;~~
 - (c) ~~an amino acid sequence of SEQ ID NO: 4; and~~
 - (d) ~~a variant of an amino acid sequence of SEQ ID NO:4, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.~~

2. – 35. (Cancelled)

36. (Currently Amended) A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

37. – 38. (Cancelled)

39. (Currently Amended) A kit comprising in one or more containers, the pharmaceutical composition of claim 36.

40. – 55. (Cancelled)

56. (New) An isolated polypeptide comprising an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 4.

Q
12

57. (New) An isolated polypeptide comprising amino acid residues 39-313 of SEQ ID NO: 4. ✓